Brief: Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026
08/03/2025 14:07
March 8 (Reuters) - Alumis Inc ALMS.O: ALUMIS INC - PHASE 3 ONWARD PROGRAM ONGOING WITH TOPLINE DATA EXPECTED IN Q1 2026 Source text: ID:nGNXRhms6 Further company coverage: ALMS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial